Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVER: TDM-guided Vedolizumab De-escalation in IBD
NCT06584162Phase 4Recruiting
- Sponsor
- University of Amsterdam
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vedolizumab in Crohn's disease, ulcerative colitis (UC), sponsored by University of Amsterdam. Started Feb 2023; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06584162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584162.